Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CNTA

CNTA - Centessa Pharmaceuticals Limited Stock Price, Fair Value and News

$25.26-0.73 (-2.81%)
Market Closed

Price Targets

CNTA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CNTA Price Action

Last 7 days

8.7%

Last 30 days

1.9%

Last 90 days

3.8%

Trailing 12 Months

52.3%

CNTA RSI Chart

CNTA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CNTA Valuation

Market Cap

3.4B

Price/Earnings (Trailing)

-13.99

Price/Sales (Trailing)

441.82

EV/EBITDA

-15.09

Price/Free Cashflow

-16.74

CNTA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

CNTA Fundamentals

CNTA Revenue

Revenue (TTM)

6.9M

Rev. Growth (Qtr)

-100%

CNTA Earnings

Earnings (TTM)

-242.7M

Earnings Growth (Yr)

-28.96%

Earnings Growth (Qtr)

-9.03%

CNTA Profitability

EBT Margin

-3492.00%

Return on Equity

-80.48%

Return on Assets

-54.14%

Free Cashflow Yield

-5.97%

CNTA Investor Care

Shares Dilution (1Y)

18.10%

Diluted EPS (TTM)

-1.9

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20230006.9M
Get all data in R, Python etc through our Historical Stock Data APIs

About Centessa Pharmaceuticals Limited

CNTA
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
 CEO
 WEBSITEcentessa.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES64

Centessa Pharmaceuticals Limited Frequently Asked Questions

CNTA is the stock ticker symbol of Centessa Pharmaceuticals Limited. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Centessa Pharmaceuticals Limited is 3.4 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CNTA's fair value in chart for subscribers.

The fair value guage provides a quick view whether CNTA is over valued or under valued. Whether Centessa Pharmaceuticals Limited is cheap or expensive depends on the assumptions which impact Centessa Pharmaceuticals Limited's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CNTA.

As of Wed Jan 28 2026, CNTA's PE ratio (Price to Earnings) is -13.99 and Price to Sales (PS) ratio is 441.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CNTA PE ratio will change depending on the future growth rate expectations of investors.